Announcements

    Drinks

      Instrument data
      Issuer
      Senority
      Senior Unsecured
      Currency
      EUR
      ISIN
      FR0013324373
      Coupon percent
      1.88%
      Coupon type
      Fixed:Plain Vanilla Fixed Coupon
      Instrument volume
      1,250,000,000
      Maturity date
      21/03/2038
      -
      AA Outlook: None
      AA Outlook: None
      Latest change
      Affirmed
      11/04/2023
      General information
      Rating
      Public
      Solicited
      With issuer participation
      UK endorsed
      EU Rated
      Philipp Wass Lead analyst
      Sebastian Zank Committee chair
      Scope affirms Sanofi’s AA/Stable issuer rating

      11/4/2023 Rating announcement EN

      Scope affirms Sanofi’s AA/Stable issuer rating

      The affirmation reflects Sanofi’s resilient operating performance and low indebtedness.

      Scope affirms Sanofi’s AA issuer rating and revises the Outlook to Stable from Positive.

      20/4/2022 Rating announcement EN

      Scope affirms Sanofi’s AA issuer rating and revises the Outlook to Stable from Positive.

      The rating action reflects our view of delayed deleveraging against our previous expectations.

      Scope Ratings affirms Sanofi's AA issuer rating and changes the Outlook to Positive

      19/5/2021 Rating announcement EN

      Scope Ratings affirms Sanofi's AA issuer rating and changes the Outlook to Positive

      The ratings continue to reflect Sanofi's improved positioning in growth sectors like rare diseases and immunology as well as management's credit-supportive financial policy.

      Scope affirms AA/Stable issuer rating on Sanofi

      9/9/2020 Rating announcement EN

      Scope affirms AA/Stable issuer rating on Sanofi

      The ratings reflect the company's leading position in a number of therapeutic areas as well as recent success with newly approved drugs contributing to a good credit metrics recovery in 2019, which Scope expects to continue.

      Scope affirms Sanofi at AA, Stable Outlook

      19/9/2019 Rating announcement EN

      Scope affirms Sanofi at AA, Stable Outlook

      The rating reflects Sanofi's leading positions in vaccines, anti-diabetics and rare diseases within a credit-supportive underlying industry as well as the strong recovery for credit metrics expected by rating agency.

      Scope affirms AA Sanofi rating

      18/9/2018 Rating announcement EN

      Scope affirms AA Sanofi rating

      The rating reflects our view of Sanofi's credit metrics' recovery to levels commensurate with the ratings following their temporary deterioration following the acquisitions of Bioverativ and Ablynx in the first half of 2018.

      French pharma Sanofi rated AA and S-1+ by Scope Ratings, Stable Outlook

      7/9/2017 Rating announcement EN

      French pharma Sanofi rated AA and S-1+ by Scope Ratings, Stable Outlook

      Scope’s first ratings for Sanofi S.A. are driven by the French group’s credit-supportive industry risk, strong competitive position and sustained track record of good credit metrics. Senior unsecured debt is rated AA.

      Date Title